Boehringer Ingelheim Ranks First Place in ‘Best Place to Work in Africa' Recognition

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, has ranked first amongst the top 15 best companies to work for in Africa by the prestigious ‘Best Places to Work’ certification program.
Based on the assessment of over 500 organizations operating across the continent, the program’s findings from this year demonstrated how well businesses across Africa have adapted to the challenges brought about by the COVID-19 pandemic.
Boehringer Ingelheim Africa was honored for its leadership, inclusive culture, commitment to professional development, agility and sense of community as key reasons employees feel proud to work for the company. 
 “Best Places To Work” is an ‘Employer of Choice’ certification that certifies and recognizes leading workplaces in many countries around the world with a rigorous assessment methodology and a framework which reflects the very latest in workplace trends focusing on eight workplace factors including leadership, HR and people policies, compensation, benefits, teamwork and relationships, employee engagement, workplace and procedures and corporate social responsibility. Their ranking is determined based on the 2020 feedback from employees gathered through anonymous surveys and an HR assessment evaluating the people management practices against outstanding workplace standards. Based on these results, that Boehringer Ingelheim Algeria have achieved earlier, Boehringer Ingelheim ranked first across the continent in this certification program in 2020. 

Mohammed Al-Tawil, Country Managing Director and Head of Human Pharma at Boehringer Ingelheim Middle East, Turkey and Africa stated on the occasion, “We are immensely proud to have our operation recognized by a prestigious program such as the Best Place to Work for in Africa. The success of a company relies on the achievements of its people and we remain committed to keep supporting our teams on their journey to success by providing them with an environment that is conducive to growth. At Boehringer Ingelheim, we value our employees and aim to continue running the family-owned company with a nurturing spirit to ensure that we foster a culture where our employees feel supported and motivated. We will continue to build upon the values that have earned us this honor, to ensure Boehringer Ingelheim remains a best place to work for in Africa.”
For 135 years, Boehringer Ingelheim has been creating value through innovation for human and animal health, dedicating itself to a better world. It aims to meet this, across its markets including Africa, through excellent HR policies and people practices, covering domains such as people strategy, work environment, talent acquisition, learning, well-being, diversity, inclusion and more. The family business invests heavily in individual development opportunities through tailor-made education and training programs for all employees. This serves to enhance its existing progressive workplace culture promoting transparency, open communication and supportive forward looking campaigns.
Boehringer Ingelheim will continue on its journey to implement further employee focused initiatives, ensuring the growth, development and overarching wellbeing of its teams.

More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

About Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life. 
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com

For more information, please contact:

Sara Shamel
Head of External Communications – META
Boehringer Ingelheim
T: +971 553258101
sara.shamel@boehringer-ingelheim.com